Seven-year outcomes following aortic valve replacement with a novel tissue bioprosthesis
The Journal of Thoracic and Cardiovascular Surgery · 2024-09 · 168 (3) · 781-791
DOI: 10.1016/j.jtcvs.2023.09.047 ↗Kurz gefasst
Klinische Studie in der Zeitschrift The Journal of Thoracic and Cardiovascular Surgery, 2024-09. Verfasst von Thomas Beaver und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Surgery, University of Florida Health, Gainesville, Fla. Electronic address: thomas.beaver@surgery.ufl.edu. Hauptthemen laut MEDLINE: Aortic Valve, Bioprosthesis, Heart Valve Prosthesis, Heart Valve Prosthesis Implantation. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Edwards Lifesciences.
Abstract (Originalsprache)
OBJECTIVE: As bioprosthetic aortic valve replacement (AVR) extends to younger cohorts, tissue durability is of paramount importance. We report 7-year outcomes from an AVR bioprosthesis utilizing novel tissue. METHODS: This was an international investigational device exemption trial for novel AVR with annual follow-up and a subset re-consented at 5 years for extended 10-year follow-up. Safety end points and echocardiographic measurements were adjudicated by an independent clinical events committee and by a dedicated core laboratory, respectively. RESULTS: Between January 2013 and March 2016, 689 patients underwent AVR with the study valve. Mean age was 66.9 ± 11.6 years, Society of Thoracic Surgeons risk score was 2.0% ± 1.8%, and 74.3% of patients were New York Heart Association functional class II and III. Five-year follow-up was completed by 512 patients, and 225 re-consented for extended follow-up. Follow-up duration was 5.3 ± 2.2 years (3665.6 patient-years), and 194 and 195 patients completed 6- and 7-year follow-ups, respectively. One-, 5-, and 7-year freedom from all-cause mortality was 97.7%, 89.4%, and 85.4%, respectively. Freedom from structural valve deterioration at 7 years was 99.3%. At 7 years, effective orifice area and mean gradients were 1.82 ± 0.57 cm2 (n = 153), and 9.4 ± 4.5 mm Hg (n = 157), respectively. At 7 years, predominantly none (96.8% [152 out of 157]) or trivial/trace (2.5% [4 out of 157]) paravalvular regurgitation and none (84.7% [133 out of 157]) or trivial/trace (11.5% [18 out of 157]) transvalvular regurgitation were observed. CONCLUSIONS: We report the longest surgical AVR follow-up with novel tissue in an investigational device exemption trial utilizing an independent clinical events committee and an echocardiography core laboratory. This tissue demonstrates excellent outcomes through 7 years and is the benchmark for future surgical and transcatheter prostheses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Cardiovascular Surgery, University of Florida Health, Gainesville, Fla. Electronic address: thomas.beaver@surgery.ufl.edu.
- Department of Cardiovascular Surgery, Hospital of the University of Pennsylvania, Philadelphia, Pa.
- Department of Surgery, University of Maryland Medical Center, Baltimore, Md.
- Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, Ohio.
- Department of Cardiology, Québec Heart and Lung Institute, Laval University, Québec, Québec, Canada.
- University Department of Cardiac Surgery, Heart Center Leipzig, Leipzig, Germany.
Förderung
- Edwards Lifesciences
Zitieren
APA
Beaver, T., Bavaria, J. E., Griffith, B., Svensson, L. G., Pibarot, P., Borger, M. A., Sharaf, O. M., Heimansohn, D. A., Thourani, V. H., Blackstone, E. H., Puskas, J. D., & COMMENCE Trial Investigators (2024). Seven-year outcomes following aortic valve replacement with a novel tissue bioprosthesis. The Journal of Thoracic and Cardiovascular Surgery, 168(3), 781-791. https://doi.org/10.1016/j.jtcvs.2023.09.047
Vancouver
Beaver T, Bavaria JE, Griffith B, Svensson LG, Pibarot P, Borger MA, et al. Seven-year outcomes following aortic valve replacement with a novel tissue bioprosthesis. The Journal of Thoracic and Cardiovascular Surgery. 2024;168(3):781-791. doi:10.1016/j.jtcvs.2023.09.047
BibTeX
@article{Beaver2024,
author = {Beaver, Thomas and Bavaria, Joseph E and Griffith, Bartley and Svensson, Lars G and Pibarot, Philippe and Borger, Michael A and Sharaf, Omar M and Heimansohn, David A and Thourani, Vinod H and Blackstone, Eugene H and Puskas, John D and COMMENCE Trial Investigators, COMMENCE Trial Investigators},
title = {Seven-year outcomes following aortic valve replacement with a novel tissue bioprosthesis},
journal = {The Journal of Thoracic and Cardiovascular Surgery},
year = {2024},
volume = {168},
number = {3},
pages = {781--791},
doi = {10.1016/j.jtcvs.2023.09.047}
}
EUVIMED